Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis | Zendy

Qingrui You | Zendy; Yongge Wu | Zendy; Yang Wu | Zendy; Wei Wei | Zendy; Changyong Wang | Zendy; Dehua Jiang | Zendy; Xianghui Yu | Zendy; Xizhen Zhang | Zendy; Yong Wang | Zendy; Zhijiao Tang | Zendy; Chunlai Jiang | Zendy; Wei Kong | Zendy

Open Access

Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis

Author(s) -

Qingrui You,

Yongge Wu,

Yang Wu,

Wei Wei,

Changyong Wang,

Dehua Jiang,

Xianghui Yu,

Xizhen Zhang,

Yong Wang,

Zhijiao Tang,

Chunlai Jiang,

Wei Kong

Publication year - 2012

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2012.07.008

Subject(s) - immunogenicity , virology , vaccination , vaccinia , heterologous , immunology , immune system , viral vector , modified vaccinia ankara , cytotoxic t cell , antigen , medicine , biology , recombinant dna , in vitro , biochemistry , gene

To evaluate regimens using bacillus Calmette-Guérin (BCG) or recombinant BCG (rBCG) overexpressing Ag85B for priming, followed by boosting with a modified vaccinia virus Ankara strain (MVA) and/or adenovirus vector (AD) expressing an Ag85B-ESAT6 fusion protein.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research